BillionToOne, a Menlo Park, Calif.-based a precision diagnostics company, closed a $15m Series A funding.
The round was led by Hummingbird Ventures and NeoTribe Ventures with participation from Y Combinator, Civilization Ventures, Fifty Years, 500 Startups Istanbul, and HOF Capital.
The company intends to use the funds to launch its first product.
Co-founded by Oguzhan Atay, PhD, and David Tao, PhD, BillionToOne is launching UNITY, a non-invasive prenatal test for recessively inherited single gene disorders.
The product, to be available later this spring, will be a prenatal cystic fibrosis and spinal muscular atrophy screening option that tests fetal cell-free DNA through a single tube of the mother’s blood.
The company plans to make diagnostic advancements in oncology liquid biopsy space next year.